STOCK TITAN

Allogene Therapeutics, Inc. - $ALLO STOCK NEWS

Welcome to our dedicated page for Allogene Therapeutics news (Ticker: $ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer and autoimmune diseases. Leveraging the expertise of former Kite Pharma executives, Allogene aims to revolutionize cancer treatment with innovative off-the-shelf CAR T solutions. These therapies, derived from healthy donor cells, provide a scalable and readily available option, eliminating the lengthy and complex process of personalized cell therapy.

The company's portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy in phase 1 development for acute lymphoblastic leukemia (ALL). Notable core programs target various malignancies such as lymphoma, leukemia, solid tumors, and autoimmune diseases. Among its leading investigational products is cemacabtagene ansegedleucel (cema-cel), currently undergoing pivotal phase 2 ALPHA3 trials for large B-cell lymphoma (LBCL) and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL). ALLO-316, aimed at renal cell carcinoma (RCC), and ALLO-329, targeting autoimmune diseases with Dagger® technology, further strengthen Allogene's robust pipeline.

Allogene collaborates with leading biotech firms like Foresight Diagnostics and Arbor Biotechnologies to enhance its clinical development capabilities. Recent achievements include strategic partnerships and a $15 million grant from the California Institute for Regenerative Medicine (CIRM) supporting the development of ALLO-316. Financially, Allogene reported a strong cash runway extending into 2026, with latest funding rounds ensuring continued support for its R&D initiatives.

Stay informed on Allogene's progress as it drives the future of allogeneic CAR T therapy, providing broader patient access and more efficient cancer treatment options.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.02%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none

FAQ

What is Allogene Therapeutics, Inc.?

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of allogeneic CAR T therapies for cancer and autoimmune diseases.

What are Allogene's core products?

Allogene's core products include UCART19, cemacabtagene ansegedleucel (cema-cel), ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune diseases.

What is unique about Allogene's therapies?

Allogene's therapies are off-the-shelf CAR T products derived from healthy donor cells, providing scalable and readily available treatment options.

Who are Allogene's key partners?

Allogene collaborates with biotech firms like Foresight Diagnostics and Arbor Biotechnologies to enhance its clinical development capabilities.

In which clinical trials is cema-cel involved?

Cema-cel is involved in the pivotal phase 2 ALPHA3 trial for large B-cell lymphoma (LBCL) and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL).

What recent financial achievement did Allogene secure?

Allogene received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the development of its ALLO-316 product.

How does Allogene's financial outlook appear?

Allogene reported a strong cash runway extending into 2026, bolstered by recent funding rounds to support continued research and development efforts.

What is the focus of Allogene's ALLO-316 trial?

The ALLO-316 trial focuses on advanced or metastatic renal cell carcinoma (RCC), assessing the safety, tolerability, and preliminary efficacy of the therapy.

What is the Dagger® technology used in ALLO-329?

Dagger® technology is used in ALLO-329 to eliminate the need for lymphodepletion while targeting CD19+ B-cells and CD70+ activated T-cells in autoimmune diseases.

What is the goal of Allogene's therapies?

Allogene aims to provide broadly accessible, scalable, and efficient cancer and autoimmune disease treatments through its pioneering allogeneic CAR T therapies.

Allogene Therapeutics, Inc.

Nasdaq:ALLO

ALLO Rankings

ALLO Stock Data

532.40M
124.55M
17.55%
64.58%
21.32%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SOUTH SAN FRANCISCO